AR011546A1 - Utilizacion de compuestos que son agonistas de los receptores beta 3 adrenergicos para la preparacion de composiciones farmaceuticas ycomposiciones farmaceuticas - Google Patents
Utilizacion de compuestos que son agonistas de los receptores beta 3 adrenergicos para la preparacion de composiciones farmaceuticas ycomposiciones farmaceuticasInfo
- Publication number
- AR011546A1 AR011546A1 ARP980100230A ARP980100230A AR011546A1 AR 011546 A1 AR011546 A1 AR 011546A1 AR P980100230 A ARP980100230 A AR P980100230A AR P980100230 A ARP980100230 A AR P980100230A AR 011546 A1 AR011546 A1 AR 011546A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- pharmaceutical compositions
- preparation
- sulfinyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title abstract 2
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title abstract 2
- -1 benzyloxy, phenoxy, mercapto Chemical class 0.000 abstract 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 abstract 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000005108 alkenylthio group Chemical group 0.000 abstract 1
- 125000005109 alkynylthio group Chemical group 0.000 abstract 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 abstract 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 210000003141 lower extremity Anatomy 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Utilizacion de los compuestos Beta3-agonistas (compuestos que son agonistas de los receptores beta-3 adrenérgicos) para la preparacion de composicionesfarmacéuticas destinadas a acelerar la cura de las heridas, particularmente para la preparacionde medicamentos cicatrizantes, más particularmente, parala preparacion de composiciones farmacéuticas destinadas a acelerar la cura de las llagas de los miembros inferiores en los mamíferos diabéticos. Algunosbeta3-agonistas utiles están representados por la formula (I), en la cual: X representa el hidrogeno, un halogeno, un grupo trifluorometilo o un grupo(C1-C4)alquilo; R representa el hidrogeno, un grupo metilo, no sustituido o sustituido por un grupo carboxi o carbalcoxi inferior ouna de sus salesfarmacéuticamente aceptables. Otros beta3-agonistas utiles están representados por la formula (II), en la cual: n es 1, 2 o 3; A representa un grupobenzofuran-2-ilo o un grupo fenilo no sustituido o sustituido por uno o dos átomos de halogeno o por un grupo (C1-C4) alquilo o trifluorometilo; R1representa: un hidrogeno, un grupo (C1-C6)alquilo, un grupo funcional elegido entre los siguientes grupos: hidroxi, (C1-C6)alcoxi, (C2-C6)alqueniloxi,(C2-C6)alquiniloxi, (C3-C8)cicloalquiloxi, (C3-C8)cicloalquil(C1-C6)alcoxi, benciloxi, fenoxi, mercapto, (C1-C6)alquiltio, (C2-C6)alqueniltio, (C2-C6)alquiniltio, (C3-C8)cicloalquiltio, (C3-C8)cicloalquil (C1-C6)alquiltio, benciltio, feniltio, ((C1-C6)alquil)sulfinilo, ((C2-C6)alquenil)sulfinilo,((C2-C6)alquinil)sulfinilo, (C3-C8)cicloalquilsulfinilo,((C3-C8)cicloalquil (C1-C6)alquil)sulfinilo, bencilsulfinilo, fenilsulfinilo, ((C1-C6)alquil)sulfonilo, ((C2-C6)alquenil)sulfonilo; ((C2-C6)alquinil)sulfonilo, ((C3-C8) cicloalquilsulfonilo, ((C3-C8)cicloalquil (C1-C6)alquil) sulfonilo,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9700584A FR2758460B1 (fr) | 1997-01-21 | 1997-01-21 | Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011546A1 true AR011546A1 (es) | 2000-08-30 |
Family
ID=9502810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100230A AR011546A1 (es) | 1997-01-21 | 1998-01-20 | Utilizacion de compuestos que son agonistas de los receptores beta 3 adrenergicos para la preparacion de composiciones farmaceuticas ycomposiciones farmaceuticas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6235793B1 (es) |
| EP (1) | EP0966276B1 (es) |
| JP (1) | JP2001508790A (es) |
| AR (1) | AR011546A1 (es) |
| AT (1) | ATE255889T1 (es) |
| AU (1) | AU5994198A (es) |
| BR (1) | BR9807288A (es) |
| CA (1) | CA2278220A1 (es) |
| DE (1) | DE69820422T2 (es) |
| FR (1) | FR2758460B1 (es) |
| HR (1) | HRP980023A2 (es) |
| NO (1) | NO326823B1 (es) |
| UY (1) | UY24848A1 (es) |
| WO (1) | WO1998031357A1 (es) |
| ZA (1) | ZA98484B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2817257B1 (fr) | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
| AU2003242250A1 (en) * | 2002-06-12 | 2003-12-31 | Sumitomo Pharmaceuticals Co., Ltd. | Cyclic amine and medicinal composition containing the same |
| US8056585B2 (en) * | 2006-12-22 | 2011-11-15 | Nkt Flexibles I/S | Flexible pipe |
| WO2008077410A1 (en) | 2006-12-22 | 2008-07-03 | Nkt Flexibles I/S | A flexible pipe |
| EP4294390A1 (en) * | 2021-02-22 | 2023-12-27 | The University Of Sydney | Wound healing methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0029320B1 (en) * | 1979-11-15 | 1985-07-10 | Beecham Group Plc | Secondary ethanol amines, their preparation and their use in pharmaceutical compositions |
| GB8528633D0 (en) * | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
| GB9308178D0 (en) * | 1993-04-21 | 1993-06-02 | Smithkline Beecham Plc | Novel compounds |
| US5578638A (en) * | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
| JPH07228543A (ja) * | 1994-02-16 | 1995-08-29 | Fujisawa Pharmaceut Co Ltd | β３−アドレナリン作動薬の新規医薬用途 |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| US5512592A (en) * | 1994-09-09 | 1996-04-30 | Wake Forest University | Method of producing cardiotonic effect and improving cardiac contractile function by administration of carnosine |
| US5597843A (en) * | 1995-06-07 | 1997-01-28 | Houghten Pharmaceuticals | Use of a substituted 1,3-benzodioxole to reduce a wasting condition |
| US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
-
1997
- 1997-01-21 FR FR9700584A patent/FR2758460B1/fr not_active Expired - Fee Related
-
1998
- 1998-01-20 HR HR9700584A patent/HRP980023A2/hr not_active Application Discontinuation
- 1998-01-20 UY UY24848A patent/UY24848A1/es not_active Application Discontinuation
- 1998-01-20 AR ARP980100230A patent/AR011546A1/es unknown
- 1998-01-21 WO PCT/FR1998/000105 patent/WO1998031357A1/fr active IP Right Grant
- 1998-01-21 AU AU59941/98A patent/AU5994198A/en not_active Abandoned
- 1998-01-21 BR BR9807288A patent/BR9807288A/pt not_active Application Discontinuation
- 1998-01-21 AT AT98903099T patent/ATE255889T1/de not_active IP Right Cessation
- 1998-01-21 CA CA002278220A patent/CA2278220A1/en not_active Abandoned
- 1998-01-21 JP JP53386198A patent/JP2001508790A/ja not_active Ceased
- 1998-01-21 US US09/341,656 patent/US6235793B1/en not_active Expired - Fee Related
- 1998-01-21 DE DE69820422T patent/DE69820422T2/de not_active Expired - Fee Related
- 1998-01-21 ZA ZA98484A patent/ZA98484B/xx unknown
- 1998-01-21 EP EP98903099A patent/EP0966276B1/fr not_active Expired - Lifetime
-
1999
- 1999-07-20 NO NO19993548A patent/NO326823B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2758460B1 (fr) | 1999-12-31 |
| HRP980023A2 (en) | 1998-10-31 |
| UY24848A1 (es) | 1998-04-21 |
| JP2001508790A (ja) | 2001-07-03 |
| WO1998031357A1 (fr) | 1998-07-23 |
| EP0966276B1 (fr) | 2003-12-10 |
| AU5994198A (en) | 1998-08-07 |
| NO993548L (no) | 1999-07-20 |
| BR9807288A (pt) | 2000-03-21 |
| ZA98484B (en) | 1998-07-30 |
| CA2278220A1 (en) | 1998-07-23 |
| EP0966276A1 (fr) | 1999-12-29 |
| DE69820422T2 (de) | 2004-10-28 |
| US6235793B1 (en) | 2001-05-22 |
| ATE255889T1 (de) | 2003-12-15 |
| DE69820422D1 (de) | 2004-01-22 |
| NO993548D0 (no) | 1999-07-20 |
| FR2758460A1 (fr) | 1998-07-24 |
| NO326823B1 (no) | 2009-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414130A (pt) | compostos de fenilamida ou piridilamida como antagonistas de prostaglandina e2 | |
| PE20020722A1 (es) | Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano | |
| PE20010749A1 (es) | Inhibidores de tirosin-cinasas | |
| BR9908474A (pt) | Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica | |
| DE60207831D1 (de) | Thiol-modifizierte hyaluronan-derivate | |
| KR900003127A (ko) | 강심제 | |
| BR9714634A (pt) | Carbamatos de benzimidazola-2 para o tratamento de infecções viróticas de câncer | |
| PT95827A (pt) | Processo para a preparacao de composicoes farmaceuticas para combater retrovirus, contendo como ingredientes activos acidos carboxilicos com enxofre | |
| KR930017873A (ko) | 피라졸 유도체, 그것을 제조하는 방법 및 그것을 함유하는 약학적 조성물 | |
| BR0206381A (pt) | Derivados do ácido fumárico como inibidor de nf-kappab | |
| PE20010684A1 (es) | Inhibidores de la reincorporacion de norepinefrina altamente selectivos y metodos para usarlos | |
| PT1213296E (pt) | Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao | |
| BR9811779A (pt) | Tetrahidro prostaglandina s substituìdas por c16-c20 aromáticos úteis como agonistas fp | |
| AR011546A1 (es) | Utilizacion de compuestos que son agonistas de los receptores beta 3 adrenergicos para la preparacion de composiciones farmaceuticas ycomposiciones farmaceuticas | |
| BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
| KR900000337A (ko) | 페놀성 티오에테르, 그의 제조방법 및 용도 | |
| BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
| PA8452701A1 (es) | Agonistas de prostaglandinas | |
| ES2182486T3 (es) | Herbicidas selectivos a base de n-aril-triazolin(tio)onas y de n-arilsulfonilamino(tio)carbonil-triazolin(tio)onas. | |
| KR880007447A (ko) | 신규 알칸술폰 아닐리드 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물 | |
| AR042967A1 (es) | Derivados de amino avermectina monosacarido sustituidos en la posicion 4' que tienen propiedades plaguicidas | |
| KR910004191A (ko) | 신질환치료제 | |
| ES2191466T3 (es) | Fenil-alquenoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamentos o agentes de diagnostico, asi como medicamentos que las contienen. | |
| BR0004143A (pt) | Composição biocida estável, e, processo para estabilizar uma composição biocida | |
| KR960037655A (ko) | 알츠하이머병 치료용 약제 |